Q3 2023 Results slide image

Q3 2023 Results

Company overview Financial review Conclusions Innovation: Pipeline overview Financial performance Cardiovascular Immunology Cardiovascular Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 44 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation